Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1396836 | 0.87 | CHRNA3 (0.68) | CHRNB4CHRNA3SLC6A2SLC6A4CHRNB2 | |
| SCHEMBL2544615 | 0.87 | CHRNA3 (0.68) | CHRNB4CHRNA3SLC6A2SLC6A4CHRNB2 | |
| Trifluoroacetic Acid SCHEMBL12487183 | 0.84 | LTA4H (0.63) | CHRNB4CHRNA3LTA4H | |
| Trifluoroacetic Acid SCHEMBL939463 | 0.84 | LTA4H (0.63) | CHRNB4CHRNA3LTA4H | |
| Trifluoroacetic Acid SCHEMBL1241015 | 0.81 | CHRNB2 (0.59) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL7897252 | 0.76 | CHRNB4 (0.63) | CHRNB4CHRNA3CHRNB2CHRNA4LTA4H | |
| SCHEMBL29039189 | 0.75 | CHRNB4 (0.59) | CHRNB4CHRNA3CHRNB2CHRNA4LTA4H | |
| Trifluoroacetic Acid SCHEMBL2201738 | 0.75 | SSTR4 (0.37) | SLC6A2SLC6A4CHRNB2CHRNA4 | |
| SCHEMBL10560065 | 0.74 | LTA4H (0.55) | CHRNB4CHRNA3SLC6A2SLC6A4CHRNB2 | |
| SCHEMBL11459124 | 0.74 | SLC6A2 (0.53) | CHRNB4CHRNA3SLC6A2SLC6A4CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912994-B1 | ADENINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-7977343-B2 | Adenine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20100160352-A1 | ADENINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-06-24 | — | — | US | disclosed |
| EP-1912994-A1 | ADENINE DERIVATIVES | Merck Patent GmbH (DE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017069-A1 | ADENINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160352-A1 | ADENINE DERIVATIVES | HSP90AA1, TRAP1, HSP90AB1 | CHRNB4 4645/4885CHRNA3 3847/4885SLC6A2 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.